REAL-TIME GLOBAL RESEARCH
JPM | US Healthcare: Pharma 2Q Prev Call 8:30am, MRK, BMY, REGN, TEVA Prevs, ALKS / LEGN / DNLI / BCRX / NVCR Re-initiations, BBIO, KNSA, NBIX, SRPT, SNDX, TVTX, RARE, ZLAB Previews, PTCT, IONS, VERA, XENE, ARWR, CNMD; KARD Initiation
Research evidence excerpt
JPM | US Healthcare: Pharma 2Q Prev Call 8:30am, MRK, BMY, REGN, TEVA Prevs, ALKS / LEGN / DNLI / BCRX / NVCR Re-initiations, BBIO, KNSA, NBIX, SRPT, SNDX, TVTX, RARE, ZLAB Previews, PTCT, IONS, VERA, XENE, ARWR, CNMD; KARD Initiation
Elif Korkmaz - Specialist Sales - US Healthcare AC North America Specialist Sales J P M O R G A Nelif.korkmaz@jpmorgan.com
J.P. Morgan Securities LLC 13 July 2026
JPM | US Healthcare: Pharma 2Q Prev Call 8:30am, MRK, BMY, REGN,
TEVA Prevs, ALKS / LEGN / DNLI / BCRX / NVCR Re-Initiations, BBIO,
KNSA, NBIX, SRPT, SNDX, TVTX, RARE, ZLAB Previews, PTCT, IONS,
VERA, XENE, ARWR, CNMD; KARD Initiation
Elif Korkmaz
+1 (212) 622 2949
elif.korkmaz@jpmorgan.com
Calls
• TODAY at 8:30am ET - PHARMA 2Q Preview CALL: Chris Schott and I will be hosting a 2Q Preview Call for Large
Cap Pharma, Spec and Animal Health at 8:30am ET. Please register here
Key Highlights
Diversified BioPharma
Merck & Co., Inc. (MRK): 2Q26 Preview: Expecting an In-Line Qtr; Focus Remains on Pipeline/sac-TMT Updates. -
Schott Note
Heading into MRK’s earnings (7/30), we anticipate no major surprises with results and see the focus of the story remaining on the
company’s pipeline, including a range of important 2026/27 readouts. On the quarter, we are slightly above the Street with sales
of $16.5bn (+$135mm) and EPS of -$0.22 (+$0.04 vs cons, inclusive of $2.35 of IPR&D and dilution from Terns acq). And for
the year, we are roughly in-line with MRK’s guidance with sales of $66.4bn (-$300mm vs cons). More broadly on the story, we
see investor focus as remaining on MRK’s range of pipeline readouts expected in 2026/2027, particularly sac-TMT updates. We
continue to believe there is a favorable risk/return for shares heading into these readouts and remain OW rated, and we raise our
The English excerpt is extracted automatically from the cited source page and may contain layout or recognition errors. It is never batch translated.
Open report viewer